A computational prospective on isoform-selective CB2 inhibitors

被引:0
|
作者
Zhao, Yi [1 ]
Wang, Ying [2 ]
Wang, Huibin [1 ]
Hu, Baichun [3 ,4 ]
Luo, Zhaohu [2 ]
Zhang, Fengjiao [2 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China
[2] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Shenyang 110016, Peoples R China
[3] Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China
[4] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China
关键词
CB1R INVERSE AGONIST; CANNABINOID RECEPTOR; OVERWEIGHT PATIENTS; MOLECULAR-DYNAMICS; ACCURATE DOCKING; DISCOVERY; POTENT; GLIDE; ANTAGONIST; TARANABANT;
D O I
10.1039/d1nj02296b
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cannabinoid (CB) receptors play a vital role in many pathophysiological processes. Selective CB2 activation may lead to the immuno-modulatory effects of cannabinoids being experienced without the psychoactive effects of CB1 activation; however, despite intense efforts, selective and potent CB2 agonists still remain to be developed likely due to the challenges associated with their unexpected CB1 affinity. The aim of this study was therefore to illuminate the selective mechanisms of CB1 and CB2 receptors via analyzing their interaction modes with highly selective ligands. It was found that although CB1 and CB2 exhibit high sequence homology, especially at ligand binding regions, the binding pocket of CB1 is a narrow cross shaped slit that is enclosed by several hydrophobic residues, whereas the binding pocket of CB2 is large and round and therefore would allow for more flexible ligands. In fact, hydrophobic interactions mainly account for the receptor-ligand interactions of both CB1 and CB2, with the key residues that determine the receptor selectivity being MET103, PHE170, VAL196, and PHE268 for CB1, and PHE87, PHE183, PHE94, and TRP194 for CB2. Therefore, the strategy of enlarging the molecular size, increasing hydrogen bond interactions with the key residues of CB2, and furthering the geometric distribution of hydrophobic groups would improve the selectivity towards the CB2 receptor. Collectively, these data shed promising light on elucidating the selective mechanisms between CB1 and CB2, which would lay a solid foundation for the future design of selective inhibitors towards CB2.
引用
收藏
页码:12688 / 12699
页数:12
相关论文
共 50 条
  • [31] Identification of novel isoform-selective inhibitors within class I histone deacetylases
    Hu, ED
    Dul, E
    Sung, CM
    Chen, ZX
    Kirkpatrick, R
    Zhang, GF
    Johanson, K
    Liu, RG
    Lago, A
    Hofmann, G
    Macarron, R
    de los Frailes, M
    Perez, P
    Krawiec, J
    Winkler, J
    Jaye, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (02): : 720 - 728
  • [32] Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness
    Scott, Sarah A.
    Selvy, Paige E.
    Buck, Jason R.
    Cho, Hyekyung P.
    Criswell, Tracy L.
    Thomas, Ashley L.
    Armstrong, Michelle D.
    Arteaga, Carlos L.
    Lindsley, Craig W.
    Brown, H. Alex
    NATURE CHEMICAL BIOLOGY, 2009, 5 (02) : 108 - 117
  • [33] Isoform-selective regulation of mammalian cryptochromes
    Simon Miller
    You Lee Son
    Yoshiki Aikawa
    Eri Makino
    Yoshiko Nagai
    Ashutosh Srivastava
    Tsuyoshi Oshima
    Akiko Sugiyama
    Aya Hara
    Kazuhiro Abe
    Kunio Hirata
    Shinya Oishi
    Shinya Hagihara
    Ayato Sato
    Florence Tama
    Kenichiro Itami
    Steve A. Kay
    Megumi Hatori
    Tsuyoshi Hirota
    Nature Chemical Biology, 2020, 16 : 676 - 685
  • [34] The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors
    Pustenko, Aleksandrs
    Nocentini, Alessio
    Gratteri, Paola
    Bonardi, Alessandro
    Vozny, Igor
    Zalubovskis, Raivis
    Supuran, Claudiu T.
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 1011 - 1020
  • [35] Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal
    Boateng, Anthony Twumasi
    Abaidoo-Myles, Araba
    Bonney, Evelyn Yayra
    Kyei, George B.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2022, 38 (08) : 615 - 621
  • [36] Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness
    Sarah A Scott
    Paige E Selvy
    Jason R Buck
    Hyekyung P Cho
    Tracy L Criswell
    Ashley L Thomas
    Michelle D Armstrong
    Carlos L Arteaga
    Craig W Lindsley
    H Alex Brown
    Nature Chemical Biology, 2009, 5 : 108 - 117
  • [37] Discovery of unglycosylated indolocarbazoles as ROCK2 isoform-selective inhibitors for the treatment of breast cancer metastasis
    Wang, Jinhui
    Gao, Tingting
    Ma, Yijun
    Zhang, Ying
    Yi, Yan
    Yan, Feihang
    Cheng, Ziyang
    Yu, Yalin
    Li, Jiaqi
    Chen, Zhe
    Ding, Wanjing
    Ma, Zhongjun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 250
  • [38] The First Structure of Human MTHFD2L and Its Implications for the Development of Isoform-Selective Inhibitors
    Scaletti, Emma R.
    Gustafsson Westergren, Robert
    Andersson, Yasmin
    Wiita, Elisee
    Henriksson, Martin
    Homan, Evert J.
    Jemth, Ann-Sofie
    Helleday, Thomas
    Stenmark, Pal
    CHEMMEDCHEM, 2022, 17 (18)
  • [39] Novel pyrazolylidene derivatives as selective CB2 agonists
    Liu, Bo
    Wang, Xueqing
    Dart, Michael
    Meyer, Michael
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [40] Novel benzimidazole derivatives as selective CB2 agonists
    Page, Daniel
    Balaux, Elise
    Boisvert, Luc
    Liu, Ziping
    Milburn, Claire
    Tremblay, Maxime
    Wei, Zhongyong
    Woo, Simon
    Luo, Xuehong
    Cheng, Yun-Xing
    Yang, Hua
    Srivastava, Sanjay
    Zhou, Fei
    Brown, William
    Tomaszewski, Miroslaw
    Walpole, Christopher
    Hodzic, Leila
    St-Onge, Stephane
    Godbout, Claude
    Salois, Dominic
    Payza, Keymal
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (13) : 3695 - 3700